Optimizing Linker Drug Design Using Next Generation Analytical Tools to Achieve DAR 8 & Greater
- Screening a diverse linker-drug library incorporating variations in payload potency, release triggers and conjugation handles to identify optimal combinations, enabling fine-tuned control over pharmacokinetics and on-target activity
- Validating conjugate solubility and aggregation states through physiochemical analytical methods to provide definitive, accessible monomer quantification
- Demonstrating in vitro cytotoxicity and selectivity for high-DAR (DAR ≥8) conjugates engineered with optimized linker-drug designs that overcome hydrophobicity-driven aggregation